PMID- 29384898
OWN - NLM
STAT- MEDLINE
DCOM- 20180209
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 52
DP  - 2017 Dec
TI  - Diagnosis and treatment of neoplastic post-transplant lymphoproliferative 
      disorder following hematopoietic stem cell transplant in beta-thalassemia: A 
      pediatric case report.
PG  - e9055
LID - 10.1097/MD.0000000000009055 [doi]
LID - e9055
AB  - INTRODUCTION: Post-transplant lymphoproliferative disorder (PTLD) is the most 
      common form of lymphoproliferation in childhood and is associated with 
      significant morbidity and mortality. In this report we reviewed the case of a 
      pediatric patient who experienced PTLD after allogeneic hematopoietic stem cell 
      transplantation (HSCT) from a human leukocyte antigen (HLA)-identical sibling. 
      METHODS: The clinical characteristics, diagnosis, and treatment of PTLD after 
      sibling HSCT in a 4-year-old boy with severe beta-thalassemia was retrospectively 
      reviewed. RESULTS: Medical records revealed the patient developed a fever and 
      superficial lymphadenopathy and soft palate enlargement 8 months post-HSCT. 
      Pathologic diagnosis indicated non-Hodgkin lymphoma (B-cell type), which resulted 
      in a reduced dose of immunosuppressant and the initiation of chemotherapy 
      (administered according to the BFM95 protocol for 2 courses; 4 courses of 
      rituximab therapy was also administered). Currently, the patient has been 
      disease-free for over 3 years. There are no specific guidelines for the treatment 
      of PTLD. The status of stem cell implantation after transplantation, and graft 
      versus host disease should be evaluated jointly, and rituximab therapy and 
      chemotherapy with BFM-95 may be used for treatment of pediatric PTLD after HSCT. 
      CONCLUSION: The current case represents a unique opportunity to review a 
      pediatric patient with beta-thalassemia. The successful treatment of post-transplant 
      non-Hodgkin B lymphoma may help other physicians in the management of similar 
      pediatric cases.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights 
      reserved.
FAU - Zhang, Xiaohong
AU  - Zhang X
AD  - Department of Hematology-Oncology, Guangzhou Women and Children's Medical Center, 
      Tianhe District, Guangzhou City, Guangdong Province, China.
FAU - Hao, Wenge
AU  - Hao W
FAU - Xu, Tao
AU  - Xu T
FAU - Liu, Sha
AU  - Liu S
FAU - Jiang, Hua
AU  - Jiang H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Child, Preschool
MH  - HLA Antigens
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/*diagnosis/etiology/*therapy
MH  - Male
MH  - beta-Thalassemia/complications/*therapy
PMC - PMC6392580
COIS- The authors report no conflicts of interest.
EDAT- 2018/02/01 06:00
MHDA- 2018/02/10 06:00
PMCR- 2017/12/29
CRDT- 2018/02/01 06:00
PHST- 2018/02/01 06:00 [entrez]
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2018/02/10 06:00 [medline]
PHST- 2017/12/29 00:00 [pmc-release]
AID - 00005792-201712290-00006 [pii]
AID - MD-D-17-06450 [pii]
AID - 10.1097/MD.0000000000009055 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(52):e9055. doi: 10.1097/MD.0000000000009055.